Affiliation
Cancer Inflammation and Immunity Group, CRUK Manchester Institute, The University of Manchester, Manchester, England, UKIssue Date
2018-01-02
Metadata
Show full item recordAbstract
In this issue of JEM, Sulciner et al. (https://doi.org/10.1084/jem.20170681) provide evidence that therapy-induced cancer cell death can, paradoxically, stimulate and accelerate the growth of surviving malignant cells by fueling tumor-promoting inflammation. Resolvins, a class of lipid mediators, counteract this effect, representing an attractive target for therapeutic intervention.Citation
Resolving the dark side of therapy-driven cancer cell death. 2018, 215(1): 9-11 J Exp MedJournal
The Journal of Experimental MedicineDOI
10.1084/jem.20172044PubMed ID
29263217Type
ArticleLanguage
enISSN
1540-9538ae974a485f413a2113503eed53cd6c53
10.1084/jem.20172044
Scopus Count
Collections
Related articles
- Die another way: Ferroptosis drives tuberculosis pathology.
- Authors: Meunier E, Neyrolles O
- Issue date: 2019 Mar 4
- TAK1ng control: TAK1 restrains NLRP3 activation.
- Authors: Mangan MS, Latz E
- Issue date: 2018 Apr 2
- A20 and ABIN-1 team up against intestinal epithelial cell death.
- Authors: Cadwell K
- Issue date: 2018 Jul 2
- Deciphering cancer fibroblasts.
- Authors: Biffi G, Tuveson DA
- Issue date: 2018 Dec 3
- Therapeutic potential of resolvins in the prevention and treatment of inflammatory disorders.
- Authors: Lee HN, Surh YJ
- Issue date: 2012 Nov 15